Epidemiologic surveillance of multi-drug resistant Pseudomonas aeruginosa in Mantova Hospital (Italy);Sorveglicmza epidemiologica di Pseudomonas aeruginosa multiresistente nell'Ospedale di Mantova

Infezioni in Medicina

Volumn 14, Issue 2, 2006, Pages 85-91

  Tomasoni, Donatella ^a   Gattuso, Gianni ^a   Chiarelli, Cristina ^b   Palvarini, Loredana ^a   Ceruti, Rossella ^c   Berra, Davide ^d   Stradoni, Raffaello ^b   Scalzini, Alfredo ^a  

^a Divisione di Malattie Infettive   (Italy)

^b Direzione Sanitaria ^*  (Italy)

^c Laboratorio di Microbiologia   (Italy)

^d CARLO POMA HOSPITAL   (Italy)

Author keywords

Antimicrobial therapy; Multi drug resistant P. aeruginosa (MDR PA); Nosocomial infections; Resistance rates; Surveillance

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; AZTREONAM; CEFTAZIDIME; CIPROFLOXACIN; IMIPENEM; PIPERACILLIN; TAZOBACTAM;

ARTICLE; BACTERIUM ISOLATION; HOSPITAL INFECTION; ITALY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; PREVALENCE; PSEUDOMONAS AERUGINOSA; BODY FLUID; CROSS INFECTION; DRUG EFFECT; GRAM NEGATIVE INFECTION; HEALTH SURVEY; HOSPITAL; HOSPITAL DEPARTMENT; HUMAN; ISOLATION AND PURIFICATION; MICROBIOLOGY; MULTIDRUG RESISTANCE; PROSPECTIVE STUDY; STATISTICS;

BODY FLUIDS; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HOSPITAL DEPARTMENTS; HOSPITALS, URBAN; HUMANS; ITALY; POPULATION SURVEILLANCE; PROSPECTIVE STUDIES; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 33746276734     PISSN: 11249390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. National Nosocomial Infection Surveillance System, 1999. National Nosocomial Infection Surveillance (NNIS) System report, data summary from January 1990- May 1999, issued June 1999. Am. J. Infect. Control, 27, 529-532, 1999.
2. Ibrahim E. H., Sherman G., Ward S., Fraser V. J., Kollef M. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 118, 146-155, 2000.
3. National Committee for Clinical Laboratory Standards. Performance Standard for Antimicrobial Susceptibility. Wayne, PA: National Committee for Clinical Laboratory Standards; eleventh imformational supplement M 100-S11, 2002.
4. Kollef M. Inadeguate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 115, 462-474, 1999.
5. Blot S., Vanderwoude K., Hoste E., Colardyn F. Reappraisal of attributable mortality in critically ill patients with nosocomial bacteremia involving Pseudomonas aeruginosa. J. Hosp. Infect. 53, 18-24, 2003.
6. Del Favero A., Menichetti F., Martino P. et al. Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) Infection Program. A multicenter, double-blind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia. Clin. Infect. Dis. 33, 1295-1301, 2001.
7. Viscoli C., Castagnola E. Treatment of febrile neutropenia: what is new? Curr. Opin. Infect. Dis. 15, 377-382, 2002.
8. Gales A. C., Jones R. N., Turnidge J., Rennie R., Ramphal R. Characterization of Pseudomonas aeruginosa isolates: occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY Antimicrobial Surveillance Program (1997-1999). Clin. Infect. Dis. 32, S146-S155, 2001.
9. Hoban D. J., Biedenbach D. J., Mutnich A. H., Jones R. N. Pathogen of occurrence and susceptibility patterns associated with pneumonia in hospitalised patients in North America: results of the SENTRY Antimicrobial Surveillance Study (2000). Diagn. Microbiol. Infect. Dis. 45, 279-285, 2003.
10. Gales A. C., Sader H. S., Jones R. N. Respiratory tract pathogens isolated from patients hospitalised with suspected pneumonia in Latin America: frequency of occurrence and antimicrobial susceptibility profile: results from the SENTRY Antimicrobial Surveillance Program (1997-2000). Diagn. Microbiol. Infect. Dis. 44, 301-311, 2002.
11. Harris A., Torres-Viera C., Venkataraman L., DeGirolami P., Samore M., Carmeli Y. Epidemiology and clinical outcomes of patients with multiresistant Pseudomonas aeruginosa. Clin. Infect. Dis. 28, 1128-1133, 1999.
12. Ortega B., Grueneveld A. B. J., Schultsz C. Endemic multidrug-resistant Pseudomonas aeruginosa in critically ill patients. Infect. Control Hasp. Epidemiol. 25, 825-831, 2004.
13. Bonten M. J., Bergmans D. C., Speijer H., Stobberingh E. E. Characteristics of polyclonal endemicity of Pseudomonas aeruginosa colonization in intensive care units: implication for infection control. Am. J. Respir. Crit. Care Med. 160, 1212-1219, 1999.
14. Jones R. N., Kirby J. T., Beach M. L., Biedenbach D. J., Pfaller M. A. Geographic variations in activity of broad spectrum beta-lactams against Pseudomonas aeruginosa: summary of the worldwide SENTRY antimicrobial surveillance program (1997-2000). Diagn. Microbiol Infect. Dis. 43, 239-243, 2002.
15. Rossolini G. M., Mantengoli E. Treatment and control of severe infections caused by multiresistant Pseudomonas aeruginosa. Clin. Microbiol. Infect. 11 (Suppl. 4), 17-32, 2005.
16. Obritsch M. D., Fish D. N., MacLaren R., Jung R. National surveillance of antimicrobial resistance in Pseudomonas aeruginosa isolates obtained from Intensive Care Unit patients from 1993 to 2002. Antimicrob. Agents Chemother. 48, 4606-4610, 2004.
17. Flamm R. K., Weaver M. K., Thornsberry C., Jones M. E., Karlowsky J. A., Sahm D. F. Factors associated with relative rates of antibiotic resistance in Pseudomonas aeruginosa isolates tested in clinical laboratories in the United States from 1999 to 2002. Antimicrob. Agents Chemother. 48, 2431-2436, 2004.
18. Bonfiglio G., Carciotto V., Russo G. et al. Antibiotic resistance in Pseudomonas aeruginosa: an Italian survey. J. Antimicrob. Chemother. 41, 307-310, 1998.
19. Fluit A. C., Verhoef J., Schimtz F. J. Antimicrobial resistance in European isolates of Pseudomonas aeruginosa. European SENTRY participants. Eur. J. Clin. Microbiol Infect. Dis. 19, 370-374, 2000.
20. Pfaller M. A., Jones M. R., Biedenbach D. J. Antimicrobial resistance trends in medical centers using carbapenems: report of 1999 and 2000 results from the MYSTIC program (USA). Diagn. Microbiol. Infect. Dis. 41, 177-182, 2001.
21. Zavascki A. P., Cruz R. P., Goldani L. Z. Risk factors for imipenem-resistant Pseudomonas aeruginosa: a comparative analysis of two case-control studies in hospitalized patients. J. Hosp. Infect. 59, 96-101, 2005.
22. Livermore D. M. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin. Infect. Dis. 34, 634-640, 2002.
23. Calandra G., Ricci F., Wang C., Brown K. Cross-resistance and imipenem. Lancet 2, 340-341, 1986.
24. Haley R.W., Culver D.H., White J.W., Morgan W.M., Emori T.G., Munn V.P., Hooton T.M. The efficacy of infection surveillance and control programs in preventing nosocomial infections in US hospitals. Am. J. Epidemiol. 121, 182-205, 1985.
25. Kwa A. L. H., Loh C., Low J. G. H., Kurup A., Tam V. H. Nebulized colistin in the treatment of pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. Clin. Infect. Dis. 41, 754-757, 2005.
26. Levin A. S., Barone A., Penco J. et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin. Infect. Dis. 28, 1008-1011, 1999.